Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19,738 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N. Yanai T, et al. Among authors: suzuki k. Int J Clin Oncol. 2018 Apr;23(2):382-388. doi: 10.1007/s10147-017-1200-4. Epub 2017 Oct 16. Int J Clin Oncol. 2018. PMID: 29039073 Clinical Trial.
Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
Nonomiya Y, Yokokawa T, Kawakami K, Kobayashi K, Aoyama T, Takiguchi T, Sugisaki T, Suzuki K, Suenaga M, Wakatsuki T, Yamaguchi K, Sugimoto Y, Hama T. Nonomiya Y, et al. Among authors: suzuki k. Oncol Res. 2019 May 7;27(5):551-556. doi: 10.3727/096504018X15291727589740. Epub 2018 Jun 18. Oncol Res. 2019. PMID: 29914591 Free PMC article.
Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
Tsuji D, Suzuki K, Kawasaki Y, Goto K, Matsui R, Seki N, Hashimoto H, Hama T, Yamanaka T, Yamamoto N, Itoh K. Tsuji D, et al. Among authors: suzuki k. Support Care Cancer. 2019 Mar;27(3):1139-1147. doi: 10.1007/s00520-018-4403-y. Epub 2018 Aug 10. Support Care Cancer. 2019. PMID: 30094732 Clinical Trial.
Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial).
Shimizu H, Suzuki K, Uchikura T, Tsuji D, Yamanaka T, Hashimoto H, Goto K, Matsui R, Seki N, Shimada T, Ikeda S, Ikegami N, Hama T, Yamamoto N, Sasaki T. Shimizu H, et al. Among authors: suzuki k. J Pharm Health Care Sci. 2018 Dec 10;4:31. doi: 10.1186/s40780-018-0128-9. eCollection 2018. J Pharm Health Care Sci. 2018. PMID: 30555710 Free PMC article.
Comparison of cisplatin-induced nephrotoxicity when using conventional versus short hydration in gastric cancer-a retrospective study.
Aoyama T, Tsunoda T, Kato H, Hagino A, Furutani R, Ito K, Yoshioka H, Nakamura M, Hiraide M, Kawakami K, Kobayashi K, Suzuki K, Ichimura T, Yamaguchi K, Hama T. Aoyama T, et al. Among authors: suzuki k. J Chemother. 2020 May;32(3):144-150. doi: 10.1080/1120009X.2020.1713507. Epub 2020 Jan 21. J Chemother. 2020. PMID: 31960769
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R, Suzuki K, Takiguchi T, Nishio M, Koike T, Hayashi T, Seto T, Kogure Y, Nogami N, Fujiwara K, Kaneda H, Harada T, Shimizu S, Kimura M, Kenmotsu H, Shimokawa M, Goto K. Matsui R, et al. Among authors: suzuki k. BMC Pharmacol Toxicol. 2020 Oct 6;21(1):72. doi: 10.1186/s40360-020-00445-y. BMC Pharmacol Toxicol. 2020. PMID: 33023657 Free PMC article.
19,738 results
You have reached the last available page of results. Please see the User Guide for more information.